GDTCHealthcare · BiotechnologyGDTC Stock Forecast: CytoMed Therapeutics Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 14 Sept 2026 — in the weakest quartile.
GDTC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores CytoMed Therapeutics Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
GDTC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GDTC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Oct 2024 | Benchmark | Reiterates | Speculative Buy | $5.00 |
| 11 June 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 4 Dec 2023 | Benchmark | Reiterates | Speculative Buy | — |
| 21 July 2023 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GDTC appears on the weeks it earns a place.
GDTC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, CytoMed Therapeutics Ltd. returned −62.5% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GDTC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
CytoMed Therapeutics Ltd. (GDTC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 10.7×
- Price / book
- 1.8×
- EV / EBITDA
- −2.1×
Cheaper than 14% of US stocks
Cheaper than 49% of US stocks
Cheaper than 72% of US stocks
- Revenue growth (YoY)
- 46.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −535.3%
- Net margin
- 79.0%
Higher than 85% of US stocks
Higher than 8% of US stocks
Higher than 98% of US stocks
- Return on equity
- −50.3%
- Return on assets
- −29.3%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CytoMed Therapeutics Ltd. (GDTC) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CytoMed Therapeutics Ltd. has a market value of $9.3M and an enterprise value of $6.3M.
forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.
CytoMed Therapeutics Ltd. employs 42 people.
Data provided by Twelve Data
GDTC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CytoMed Therapeutics Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about GDTC stock
Is GDTC stock a buy right now?
Of the 1 analysts covering CytoMed Therapeutics Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytoMed Therapeutics Ltd. 17 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GDTC?
As at 14 Sept 2026, CytoMed Therapeutics Ltd. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
What is the GDTC stock forecast for 2030?
No analyst covering CytoMed Therapeutics Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GDTC are extrapolating price history, which says nothing about the business.
How has GDTC stock performed over the past year?
CytoMed Therapeutics Ltd. returned -62.5% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CytoMed Therapeutics Ltd. do?
CytoMed Therapeutics Ltd. is a Singapore-based biopharmaceutical company focused on developing cell-based immunotherapies for cancer and other serious diseases.
About CytoMed Therapeutics Ltd.
CytoMed Therapeutics Ltd. is a Singapore-based biopharmaceutical company focused on developing cell-based immunotherapies for cancer and other serious diseases. Its current pipeline centers on innate immune cell and stem cell-based technologies, including gamma delta T-cell, natural killer T-cell, and pluripotent stem cell platforms designed to support novel therapeutic candidates. The company’s work includes research, development, processing, and banking of cells, with an emphasis on allogeneic approaches that use donor-derived materials. CytoMed Therapeutics Ltd. operates primarily in Singapore and Malaysia, serving the growing biotechnology and advanced therapy markets in Asia. Its role in the financial market is tied to the high-potential but research-intensive biopharmaceutical sector, where progress depends on clinical development, regulatory milestones, and platform innovation.
CEO Dr. Wee Kiat Tan Ph.D. · 42 employees · Singapore · https://w2.cytomed.sg